# Hour 12: 12:00-12:59 - Peak Morning Ending

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 12 marks the end of the peak morning window with 11 new patient arrivals
(PAT-ODMND-0086 through PAT-ODMND-0096), sustaining high throughput as the
facility transitions toward the early afternoon period. The site reaches
approximately 25 concurrent patients, engaging 16 of 29 robot instances across
all 10 robot types at approximately 55% overall utilization. PAT-ODMND-0065's
surgical procedure completes successfully at 12:15 after 95 minutes of
operative time, achieving R0 resection margins. PAT-ODMND-0079's surgery
continues from the prior hour. The lunch period introduces a slight dip in
robot utilization as several morning-wave procedures complete and patients
transition to recovery observation. Investigational drugs are administered to
two patients under IND protocol: temozolomide for PAT-ODMND-0088
(glioblastoma) and sorafenib for PAT-ODMND-0091 (HCC ablation). No adverse
events occur this hour. PSL advances to 64.8 on a +0.1 increase to Rehab
Exoskeleton Dimension C (Omnipotent), reflecting consistent gait training
outcomes across multiple patients.

## Regulatory Framework References

This simulation hour is conducted under three adapted regulatory frameworks:

- ICH E6(R3) Adaption (DOI: 10.5281/zenodo.18973368) - Good Clinical Practice
  guidelines adapted for Physical AI autonomous clinical trial operations.
- 21 CFR Part 50 Adaption (DOI: 10.5281/zenodo.19040707) - Protection of human
  subjects adapted for robotic-mediated informed consent and safety oversight.
- 21 CFR Part 312 Adaption (DOI: 10.5281/zenodo.19057628) - Investigational
  New Drug regulations adapted for Physical AI trial IND management.

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. The single-patient cancer journey framework
(Kawchak, 2026; DOI: 10.5281/zenodo.19119939) demonstrated autonomous
Physical AI trial orchestration for an individual patient.

## Site Status at 12:00

- Total patients on-site: ~25 (continuing from Hours 08-11 plus new arrivals)
- Active procedures: 2 (P0065 surgery in progress, P0079 surgery in progress)
- Robots in active mode: 4 (SURG-01 with P0065, SURG-02 with P0079,
  plus 2 companion robots with pediatric patients)
- Robots in standby mode: 25
- Robots in maintenance: 0
- Queue length: 0 across all stations
- Site safety officer on duty: SSO-D1 (day shift)

## Hour Timeline Overview

```
TIME  EVENT                                          ROBOT       PATIENT
----  -----                                          -----       -------
12:00 Peak morning ending period begins              --          --
12:02 Arrival: RT tracking (SCLC)                    TRACK-01    P0086
12:05 P0086 RT tracking setup begins                 TRACK-01    P0086
12:08 Arrival: cobot biopsy (forearm sarcoma)         COBOT-01    P0087
12:10 P0087 cobot biopsy prep begins                 COBOT-01    P0087
12:12 Arrival: RT positioning (glioblastoma)          RTPOS-02    P0088
12:14 P0088 RT positioning prep begins               RTPOS-02    P0088
12:15 P0065 surgery completes (95 min, R0 resection) SURG-01     P0065
12:16 Arrival: pediatric companion (AML)              COMPN-05    P0089
12:18 P0089 companion session begins                 COMPN-05    P0089
12:20 Arrival: needle placement (parotid tumor)       NEEDLE-01   P0090
12:22 P0090 needle placement prep begins             NEEDLE-01   P0090
12:24 Arrival: imaging + ablation (HCC)               IMAGE-01    P0091
12:26 P0091 imaging phase begins                     IMAGE-01    P0091
12:28 Arrival: humanoid therapy (ped osteosarcoma)    HUMAN-01    P0092
12:30 P0092 humanoid therapy begins                  HUMAN-01    P0092
12:32 Arrival: imaging (liver mets)                   IMAGE-02    P0093
12:34 P0093 imaging begins                           IMAGE-02    P0093
12:36 Arrival: RT tracking (NSCLC adenocarcinoma)     TRACK-02    P0094
12:38 P0094 RT tracking setup begins                 TRACK-02    P0094
12:40 Arrival: cobot biopsy (forearm sarcoma)         COBOT-02    P0095
12:42 P0095 cobot biopsy prep begins                 COBOT-02    P0095
12:45 P0091 imaging complete, ablation transfer       STEER-01    P0091
12:48 Arrival: rehab exoskeleton (fem osteosarcoma)   REHAB-03    P0096
12:50 P0096 rehab session begins                     REHAB-03    P0096
12:55 P0091 ablation procedure begins                STEER-01    P0091
12:59 End of hour - 16 robots active                 --          --
```

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage | ECOG | Robot Assigned |
|-----------|------|-----|-----|-------------|-------|------|---------------|
| PAT-ODMND-0086 | 12:02 | 55 | M | Small cell lung cancer (SCLC) | III | 1 | TRACK-01 |
| PAT-ODMND-0087 | 12:08 | 42 | F | Forearm sarcoma | II | 0 | COBOT-01 |
| PAT-ODMND-0088 | 12:12 | 71 | M | Glioblastoma | IV | 2 | RTPOS-02 |
| PAT-ODMND-0089 | 12:16 | 6 | M | Pediatric AML | -- | 1 | COMPN-05 |
| PAT-ODMND-0090 | 12:20 | 63 | F | Parotid tumor | I | 0 | NEEDLE-01 |
| PAT-ODMND-0091 | 12:24 | 58 | M | Hepatocellular carcinoma (HCC) | III | 1 | IMAGE-01, STEER-01 |
| PAT-ODMND-0092 | 12:28 | 14 | M | Pediatric osteosarcoma | -- | 1 | HUMAN-01 |
| PAT-ODMND-0093 | 12:32 | 67 | F | Liver metastases | IV | 2 | IMAGE-02 |
| PAT-ODMND-0094 | 12:36 | 49 | M | NSCLC adenocarcinoma | IIB | 1 | TRACK-02 |
| PAT-ODMND-0095 | 12:40 | 38 | F | Forearm sarcoma | I | 0 | COBOT-02 |
| PAT-ODMND-0096 | 12:48 | 70 | M | Femur osteosarcoma | -- | 2 | REHAB-03 |

### PAT-ODMND-0086 (55M, SCLC, Stage III, ECOG 1)
Patient is a 55-year-old male with Stage III small cell lung cancer presenting
for robotic RT motion-tracking treatment. Prior platinum-etoposide chemotherapy
completed 3 weeks ago with partial response. Current treatment plan includes
concurrent chemoradiation with RT tracking for respiratory-gated delivery.
TRACK-01 assigned for real-time tumor motion compensation during beam delivery.

### PAT-ODMND-0087 (42F, Forearm Sarcoma, Stage II, ECOG 0)
Patient is a 42-year-old female with Stage II forearm soft tissue sarcoma
presenting for robotic cobot-assisted incisional biopsy to determine histologic
subtype. MRI demonstrates a 4.2 cm mass in the volar compartment. COBOT-01
assigned for precision tissue sampling under ultrasound guidance.

### PAT-ODMND-0088 (71M, Glioblastoma, Stage IV, ECOG 2)
Patient is a 71-year-old male with newly diagnosed glioblastoma multiforme
presenting for RT positioning and treatment planning. Post-craniotomy (3 weeks
prior) with residual enhancing disease. Temozolomide administered per IND
protocol concurrent with RT per Stupp regimen. RTPOS-02 assigned for
thermoplastic mask fitting and CT simulation.

### PAT-ODMND-0089 (6M, Pediatric AML, ECOG 1)
Patient is a 6-year-old male with acute myeloid leukemia presenting for
companion robot support during induction chemotherapy monitoring. Parent
present and consented per 21 CFR Part 50 Subpart D (additional protections
for children). COMPN-05 assigned for age-appropriate engagement and anxiety
reduction during extended monitoring session.

### PAT-ODMND-0090 (63F, Parotid Tumor, Stage I, ECOG 0)
Patient is a 63-year-old female with Stage I parotid gland tumor presenting
for CT-guided needle biopsy to confirm histology prior to surgical planning.
Tumor measures 1.8 cm on imaging. NEEDLE-01 assigned for precise needle
placement with real-time CT guidance to avoid facial nerve proximity.

### PAT-ODMND-0091 (58M, HCC, Stage III, ECOG 1)
Patient is a 58-year-old male with Stage III hepatocellular carcinoma
presenting for combined imaging assessment and ablation therapy. Two lesions
identified on prior imaging: Segment V (3.1 cm) and Segment VIII (2.4 cm).
Sorafenib administered per IND protocol as adjunct to thermal ablation.
IMAGE-01 assigned for pre-ablation mapping, STEER-01 assigned for
steerable needle ablation of both lesions.

### PAT-ODMND-0092 (14M, Pediatric Osteosarcoma, ECOG 1)
Patient is a 14-year-old male with osteosarcoma of the proximal tibia
presenting for humanoid robot-assisted physical therapy and psychosocial
support following limb-salvage surgery (4 weeks prior). HUMAN-01 assigned
for guided range-of-motion exercises and motivational interaction during
rehabilitation phase. Parent consented per 21 CFR Part 50 Subpart D.

### PAT-ODMND-0093 (67F, Liver Metastases, Stage IV, ECOG 2)
Patient is a 67-year-old female with Stage IV colorectal cancer with hepatic
metastases presenting for surveillance imaging to assess response to ongoing
systemic therapy. CEA trending upward from 12.4 to 18.7 ng/mL. IMAGE-02
assigned for multi-phase liver CT with AI-enhanced lesion tracking.

### PAT-ODMND-0094 (49M, NSCLC Adenocarcinoma, Stage IIB, ECOG 1)
Patient is a 49-year-old male with Stage IIB non-small cell lung cancer
(adenocarcinoma subtype) presenting for definitive RT with motion tracking.
Tumor located in the right lower lobe with mediastinal nodal involvement.
TRACK-02 assigned for respiratory-gated beam delivery with real-time tumor
position verification.

### PAT-ODMND-0095 (38F, Forearm Sarcoma, Stage I, ECOG 0)
Patient is a 38-year-old female with Stage I forearm sarcoma presenting for
cobot-assisted core needle biopsy. Palpable 2.1 cm mass in the dorsal
forearm compartment identified on ultrasound 2 weeks prior. COBOT-02
assigned for ultrasound-guided tissue acquisition.

### PAT-ODMND-0096 (70M, Femur Osteosarcoma, ECOG 2)
Patient is a 70-year-old male with osteosarcoma of the distal femur presenting
for rehabilitation exoskeleton-assisted gait training. Post-endoprosthetic
reconstruction (6 weeks prior). Limited weight-bearing status. REHAB-03
assigned for progressive gait training with force-feedback monitoring.

## Continuing Patients at 12:00

| Patient ID | Age | Sex | Cancer Type | Status | Since |
|-----------|-----|-----|-------------|--------|-------|
| PAT-ODMND-0065 | 52 | M | Mediastinal tumor | Surgery in progress (SURG-01) | 10:40 |
| PAT-ODMND-0079 | 61 | F | Pancreatic adenocarcinoma | Surgery in progress (SURG-02) | 11:15 |

Additional continuing patients include approximately 12-14 patients in
various stages of post-procedure observation and recovery from Hours 08-11,
plus 2 pediatric patients under companion monitoring.

## Surgical Completion: PAT-ODMND-0065

PAT-ODMND-0065 (52M, mediastinal tumor) surgical resection via SURG-01
completes at 12:15 after 95 minutes of operative time (began 10:40).

- Procedure: Robotic-assisted thoracoscopic mediastinal tumor resection
- Robot: SURG-01 (Surgical Suite 1)
- Operative duration: 95 minutes
- Estimated blood loss: 185 mL
- Resection margins: R0 (microscopically negative, confirmed by intraoperative
  frozen section)
- Specimen weight: 78 g
- Lymph nodes sampled: 4 mediastinal stations, 11 nodes total
- Complications: None
- Drain placed: 1 Jackson-Pratt drain, left chest
- Patient transferred to Recovery Bay 1 at 12:20 in stable condition
- SURG-01 cleaning cycle initiated at 12:20, completed 12:35, returned
  to standby

Minute-by-minute summary (final 15 minutes of surgery):
- 12:00 - Hemostasis check of mediastinal bed, irrigation
- 12:02 - Final inspection of resection cavity, no residual tumor
- 12:04 - Drain placement, secured with suture
- 12:06 - Specimen orientation marked, sent to pathology
- 12:08 - Chest closure initiated, port sites closed
- 12:10 - Skin closure completed, dressings applied
- 12:12 - Anesthesia reversal initiated
- 12:14 - Patient extubated, spontaneous ventilation confirmed
- 12:15 - Surgery declared complete, operative time 95 minutes
- 12:18 - Patient transferred to recovery stretcher
- 12:20 - Patient arrives Recovery Bay 1, post-operative monitoring begins

## Continuing Surgery: PAT-ODMND-0079

PAT-ODMND-0079 (61F, pancreatic adenocarcinoma) surgical resection via SURG-02
continues from Hour 11 (began 11:15). At 12:00 the case is 45 minutes into the
procedure (pancreatic dissection phase). The surgical team reports meticulous
dissection around the superior mesenteric artery with no vascular compromise.
Expected completion: approximately 13:45 (estimated 150-minute procedure).

- 12:00 - Superior mesenteric artery dissection ongoing, no bleeding
- 12:15 - Portal vein exposure complete, tumor mobilization continuing
- 12:30 - Uncinate process division initiated
- 12:45 - Pancreatic neck transection complete, specimen being freed
- 12:59 - Biliary-enteric anastomosis preparation beginning

## Patient Departures This Hour

| Patient ID | Time | Outcome | Notes |
|-----------|------|---------|-------|
| PAT-ODMND-0068 | 12:10 | Discharged | Post-RT observation complete, skin assessment stable |
| PAT-ODMND-0071 | 12:25 | Discharged | Post-imaging results reviewed, follow-up scheduled |
| PAT-ODMND-0074 | 12:35 | Discharged | Post-biopsy wound stable, pathology pending |
| PAT-ODMND-0076 | 12:45 | Discharged | Post-needle procedure observation complete |

## End-of-Hour Census

| Patient ID | Age | Sex | Cancer Type | Status | Location |
|-----------|-----|-----|-------------|--------|----------|
| PAT-ODMND-0065 | 52 | M | Mediastinal tumor | Post-surgical recovery | Recovery Bay 1 |
| PAT-ODMND-0079 | 61 | F | Pancreatic adenocarcinoma | Surgery in progress | Surgical Suite 2 |
| PAT-ODMND-0086 | 55 | M | SCLC | Active RT tracking | RT Vault 1 |
| PAT-ODMND-0087 | 42 | F | Forearm sarcoma | Active cobot biopsy | Biopsy Station 1 |
| PAT-ODMND-0088 | 71 | M | Glioblastoma | Active RT positioning | RT Vault 2 |
| PAT-ODMND-0089 | 6 | M | Pediatric AML | Companion session | Companion Area 5 |
| PAT-ODMND-0090 | 63 | F | Parotid tumor | Active needle placement | CT Suite 1 |
| PAT-ODMND-0091 | 58 | M | HCC | Active ablation | Ablation Suite 1 |
| PAT-ODMND-0092 | 14 | M | Pediatric osteosarcoma | Humanoid therapy | Humanoid Station 1 |
| PAT-ODMND-0093 | 67 | F | Liver mets | Post-imaging observation | Recovery Bay 4 |
| PAT-ODMND-0094 | 49 | M | NSCLC adenocarcinoma | Active RT tracking | RT Vault 3 |
| PAT-ODMND-0095 | 38 | F | Forearm sarcoma | Active cobot biopsy | Biopsy Station 2 |
| PAT-ODMND-0096 | 70 | M | Femur osteosarcoma | Active rehab | Rehab Bay 3 |

Additional patients in observation and recovery from prior hours bring the
total on-site census to approximately 25 patients at 12:59.

## Adverse Events

None this hour.

## Investigational Drug Administrations

### Temozolomide - PAT-ODMND-0088

- Patient: PAT-ODMND-0088 (71M, glioblastoma, Stage IV)
- Drug: Temozolomide 75 mg/m2 oral daily
- IND protocol: Concurrent chemoradiation per Stupp regimen
- Administration time: 12:14 (prior to RT positioning session)
- Route: Oral
- Dose verification: Pharmacy dispensed, AI dosimetry check confirmed
  BSA-appropriate dose
- AE monitoring: Per 21 CFR Part 312.32, continuous monitoring for nausea,
  myelosuppression, hepatotoxicity. No immediate AEs observed.
- Prior labs: WBC 4.2, Platelets 156, ALT 28 (within protocol limits)

### Sorafenib - PAT-ODMND-0091

- Patient: PAT-ODMND-0091 (58M, HCC, Stage III)
- Drug: Sorafenib 400 mg oral BID
- IND protocol: Neoadjuvant to thermal ablation for HCC
- Administration time: 12:24 (concurrent with imaging assessment)
- Route: Oral
- Dose verification: Pharmacy dispensed, drug interaction check with ablation
  protocol cleared. No contraindication to concurrent thermal ablation.
- AE monitoring: Per 21 CFR Part 312.32, monitoring for hand-foot syndrome,
  diarrhea, hypertension. BP at administration: 132/78. No immediate AEs.
- Prior labs: AFP 284, Child-Pugh A, bilirubin 1.1

## Site Utilization

- Overall robot utilization: ~55% (16 of 29 instances active at peak,
  slight dip from morning wave as completed procedures transition to recovery)
- Queue lengths: 0 across all stations (lunch period eases pressure)
- Average wait time: 2.4 minutes (across 11 arrivals)
- Robot cleaning cycles: 2 (SURG-01 post-surgery, IMAGE-01 post-imaging)
- Concurrent patients at peak: ~25

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- Section 1.1.1: All procedures conducted in accordance with ethical principles
  and applicable GCP requirements. Surgical completion for P0065 followed full
  specimen documentation and pathology chain-of-custody protocols.
- Section 2.9.1: Complete audit trail maintained for all 11 new patient
  arrivals including check-in timestamps, robot assignment logs, consent
  verification records, and procedure initiation logs.
- Section 2.10.1: Adverse event surveillance active for all concurrent
  patients. Zero AEs reported during Hour 12. Continuous pharmacovigilance
  for temozolomide (P0088) and sorafenib (P0091) per protocol.
- Section 4.2.1: Data capture for P0065 surgical completion includes operative
  duration, blood loss, margin status, specimen measurements, and drain output
  with synchronized UTC timestamps.

### 21 CFR Part 50 - Adaption
- Section 50.25: All 11 new patients completed informed consent including
  Physical AI system disclosure, USL readiness scores, and right to
  non-Physical AI alternatives prior to procedure initiation.
- Section 50.25(a)(5): IND drug consent elements verified for P0088
  (temozolomide) and P0091 (sorafenib), including investigational nature,
  alternative treatments, and right to withdraw.
- Subpart D: Pediatric protections applied for PAT-ODMND-0089 (6M, AML)
  and PAT-ODMND-0092 (14M, osteosarcoma). Parental consent and age-appropriate
  assent obtained. IRB-approved pediatric safety monitoring protocols active.
- Section 50.30: Pre-procedure safety matrix completed for all 11 patients:
  authorization verified, identity confirmed, clinical data accessed via FHIR,
  robot readiness confirmed, environmental checks passed.

### 21 CFR Part 312 - Adaption
- Section 312.32: Safety reporting systems active and monitoring all patients.
  No reportable events this hour. IND drug monitoring ongoing for P0088
  and P0091 with scheduled lab draws at next protocol-defined intervals.
- Section 312.62: Investigator recordkeeping maintained for all on-site
  patients including Physical AI system interaction logs, vital sign records,
  drug administration records, and procedure documentation.
- Section 312.50: IND sponsor notification systems operational. Temozolomide
  and sorafenib administration records transmitted to sponsor database within
  protocol-defined timeframes.

## Complementary Framework References

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. All 10 robot types engaged this hour demonstrate
platform-level USL scores consistent with the Advanced band, reflecting
strong sensor integration, AI-driven decision support, and cross-framework
validation coverage across Isaac Lab, MuJoCo, Gazebo, and PyBullet.

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial
orchestration for an individual patient. Hour 12 operations extend this
framework to approximately 25 concurrent patients spanning 11 distinct
cancer types with multi-robot coordination across surgical, radiotherapy,
imaging, biopsy, ablation, companion, humanoid, and rehabilitation modalities.
